Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2009 Record Financial Results
- Conference call scheduled Tuesday, April 6, 2010 at 9:00 a.m. EDT - - Provides full year 2010 sales guidance of $67.1 million to $72.5 million - BEIJING, April 6 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today its unaud...
Sinovac to Host Conference Call to Report 2009 Fourth Quarter Financial Results
BEIJING, March 29 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Tuesday, April 6, 2010 at 9:00 a.m. ET to review the Company's financial results for the fourth quarter and year ended Decemb...
Sinovac Enters Exclusive Supply and Distribution Agreements with Parenteral Biotech Ltd. for India
BEIJING, March 29 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today it has entered into exclusive license, supply and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-...
Sinovac to Present at Inaugural China Healthcare Investment Conference
BEIJING, March 23 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that Mr. Weidong Yin, Chairman, President and CEO of Sinovac, is scheduled to partake in Track One: Pharmaceuticals and Biotech at the Inaugural China Healthcare...
Sinovac Completes Acquisition Aimed at Expanding Production Capacity
BEIJING, Feb. 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, today announced the completion by its subsidiary, Sinovac Beijing, of the acquisition of buildings and land use rights. The total consideration for the purchase is approximately ...
Sinovac Announces Closing of Common Share Offering
BEIJING, Feb. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, announced today that its previously announced public common share offering was closed on February 2, 2010. Sinovac received net proceeds of approximat...
Sinovac Announces Exercise of Over-Allotment Option
BEIJING, Feb. 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, announced today that the underwriters of its previously announced public common share offering have exercised in full their option to purchase an addi...
Sinovac Announces Upsizing and Pricing of Common Share Offering
BEIJING, Jan. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, announced today that it has priced its public offering of 10,000,000 common shares at $5.75 per common share. Sinovac has granted the underwriters a...
Sinovac Announces Plan to Launch Offering of Common Shares
BEIJING, Jan. 21 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, today announced that it plans to sell, subject to market and other conditions, 8,650,000 common shares of the company in an underwritten public offering. Sinovac plans to grant t...
Sinovac Announces Recent Developments
BEIJING, Jan. 21 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, today announced the following recent developments. Dalian Joint Venture In November 2009, Sinovac, through its wholly owned subsidiary ...
Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
BEIJING, Jan. 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has received its fifth purchase order for its H1N1 vaccine, PANFLU.1(TM), from China's Ministry of Industry and Information Technology for ...
Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
BEIJING, Dec. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has filed the application with China's State Food and Drug Administration (SFDA) to commence a human clinical trial for its vaccine against...
Sinovac's CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
BEIJING, Dec. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Weidong Yin, Chairman, President & CEO, was presented with the Annual Innovation Award by China Central Television (CCTV). As previously anno...
Sinovac Named One of China's Top 10 Most Competitive Companies Listed Overseas in 2009
BEIJING, Dec. 21 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac was selected by China Business Media as one of China's Top 10 most competitive companies listed overseas for 2009. The honor was given...
Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award
BEIJING, Dec. 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Weidong Yin, Chairman, President & CEO, was selected by China Central Television (CCTV) to be one of 18 nominees for China's 2009 Economic Man...
Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government
BEIJING, Dec. 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that it has received its fourth purchase order for its H1N1 vaccine, PANFLU.1(TM), from China's Ministry of Industry and Information Technology for th...
Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
-Sinovac to Own 55% in Joint Venture by Year End 2010- BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Tec...
Sinovac to Present at Piper Jaffray Health Care Conference
BEIJING, Nov. 24 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that management is scheduled to present at the Piper Jaffray Health Care Conference on Wednesday, December 2, 2009 at 8 a.m. Eastern time. The conf...
Sinovac Files Shelf Registration Statement
BEIJING, Nov. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today that it has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission. Mr. Weidong Yin, Chairman, President and ...
Sinovac's PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
BEIJING, Nov. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines in China, announced today that it received a revised production license from State Food and Drug Administration for Panflu.1, the Company's H1N1 vaccine. The population has be...
